GLP-1-based therapy in older adults with diabetes

Chee W. Chia, Josephine M. Egan

Research output: Contribution to journalArticle

Abstract

Aging is known to be associated with an increased prevalence of diabetes. In 2005, the CDC reported an estimated prevalence of diabetes in the U.S. to be 2% in the 20-39 age group, 10% in the 40-59 age group, and 21% in the 60 or older age group. Glucagon-like peptide-1 (GLP-1), a hormone secreted postprandially from enteroendocrine L cells, has potent insulinotropic effects. In addition, it suppresses glucagon secretion during hyperglycemia, delays gastric emptying, slows gut motility, and increases satiety; all work in synergy to normalize hyperglycemia in diabetes. In this review, the authors summarize the biology of GLP-1, explore the latest development of GLP-1 analogs and GLP-1 receptor agonists for treatment of type 2 diabetes, and discuss how this new class of agents may be suitable for treating older patients with diabetes.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalClinical Geriatrics
Volume15
Issue number4
StatePublished - Apr 2007
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Chia, C. W., & Egan, J. M. (2007). GLP-1-based therapy in older adults with diabetes. Clinical Geriatrics, 15(4), 27-34.